Logo of Anatara Lifesciences (ASX:ANR)Latest Anatara Lifesciences (ASX:ANR) News

Page 1
Page 1 of 2

Anatara flags funding uncertainty as AOC obesity project remains on hold

Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
23 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Anatara Moves AOC Toward Manufacturing Without Another Clinical Trial

Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
13 Oct 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Anatara Lifesciences Navigates Mixed Anti-Obesity Data and Tight Cash Position

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.
Ada Torres
29 Apr 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026

Anatara Lifesciences Halves Loss, Advances Anti-Obesity Research Amid $1.2m Capital Raise

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.
Ada Torres
25 Feb 2026

Anatara Lifesciences Unveils Promising Anti-Obesity Compound Amid $1.2M Capital Raise

Anatara Lifesciences reports encouraging interim pre-clinical results for its Anti-Obesity Project, with a candidate compound showing significant effects on weight regain and visceral fat in mice. The company also completed a $1.2 million capital raise, bolstering its financial position as it advances research.
Ada Torres
30 Jan 2026

Anatara’s AOC Compound Shows Promise in Pre-Clinical Weight Control Study

Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.
Ada Torres
17 Dec 2025

Anatara Lifesciences Finalises 66 Million Share Placement, Issues Options to Lead Manager

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.
Ada Torres
26 Nov 2025

Anatara Lifesciences Advances Anti-Obesity Trials, Secures $1.2M Placement

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.
Ada Torres
23 Oct 2025

Anatara Lifesciences Issues 33.6 Million Shares in First Placement Tranche

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.
Ada Torres
8 Oct 2025